health pharma news today obesity drugs glp-1 october 2025 Outlook for obesity in 2025: more Weight loss with GLP-1 medicines

Current Status of Ozempic Litigation The Ozempic litigation has grown into one of the largest pharmaceutical mass torts in recent history, with numerous Ozempic lawsuits and case numbers accelerating rapidly throughout 2025 as more patients discover connections between their injuries and GLP-1 medications

ESC heart failure

Read Time: 11 min read Key Takeaways Litigation status: Lawsuits involving Ozempic and other GLP-1 drugs have been grouped together in two separate multidistrict litigations (MDL), helping to expedite the legal process

North America is expected to lead the market, holding a share of 32.3% in 2026

(2024) 10:e136

While the published study focused primarily on SGLT2is and reported improvements in DHEAS and menstrual irregularity, our meta-analysis included a broader range of interventions (GLP-1 RAs alone and in combination) and found more pronounced hormonal benefits, such as significant reductions in FAI and testosterone with SGLT2is, outperforming GLP-1 RAs in these aspects